Page 82 - Read Online

Serzan et al. J Cancer Metastasis Treat 2021;7:39 https://dx.doi.org/10.20517/2394-4722.2021.76 Page 17 of 19

DOI PubMed PMC
15. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI PubMed PMC
16. Motzer RJ, Tannir NM, McDermott DF, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus sunitinib in advanced
renal-cell carcinoma. N Engl J Med 2018;378:1277-90. DOI PubMed PMC
17. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell
Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141-8. DOI PubMed PMC
18. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies
against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96. DOI PubMed
19. Jubb AM, Pham TQ, Hanby AM, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic
anhydrase IX in human tumours. J Clin Pathol 2004;57:504-12. DOI PubMed PMC
20. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-
121. DOI PubMed PMC
21. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12:699-709. DOI PubMed PMC
22. Lai Y, Zhao Z, Zeng T, et al. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell
carcinoma. Cancer Cell Int 2018;18:31. DOI PubMed PMC
23. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib
versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014;32:1412-8. DOI PubMed
24. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med 2007;356:2271-81. DOI PubMed
25. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib
versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765-72.
DOI PubMed PMC
26. Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw
2020;18:1160-70. DOI PubMed
27. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene
2016;35:2687-97. DOI PubMed PMC
28. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of
intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and
overall survival update. Eur J Cancer 2018;94:115-25. DOI PubMed PMC
29. Motzer R, Alekseev B, Rha SY, et al; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal
Cell Carcinoma. N Engl J Med 2021;384:1289-300. DOI PubMed
30. Hutson TE, Lesovoy V, Al-shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell
carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287-94. DOI PubMed
31. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell
carcinoma: results from a phase III trial. J Clin Oncol 2013;31:3791-9. DOI PubMed PMC
32. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall
survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62. DOI PubMed
33. Rini BI, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3,
multicentre, randomised, controlled, open-label study. Lancet Oncol 2020;21:95-104. DOI PubMed
34. McDermott DF, Cheng SC, Signoretti S, et al. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive
models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21:561-8. DOI PubMed PMC
35. Coppin C, Porzsolt F, Autenrieth M, et al. Immunotherapy for advanced renal cell cancer. Cochrane database of systematic reviews.
Chichester: John Wiley & Sons, Ltd; 1996.
36. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012;12:307-13. DOI
PubMed PMC
37. Kopecky O, Lukesová S, Vroblová V, et al. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral
blood in patients with renal carcinoma. Acta Medica (Hradec Kralove) 2007;50:207. PubMed
38. Komohara Y, Hasita H, Ohnishi K, et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.
Cancer Sci 2011;102:1424-31. DOI PubMed
39. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. DOI PubMed
40. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol
2011;11:852-63. DOI PubMed
41. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 2017;8:2171. DOI PubMed
PMC
42. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell
carcinoma: the CheckMate 016 study. J Clin Oncol 2017;35:3851-8. DOI PubMed PMC
43. Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus
ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer 2020;8:e000891. DOI PubMed PMC
44. Tannir NM, McDermott DF, Escudier B, Hammers HJ, et al. Overall survival and independent review of response in CheckMate 214